These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32385388)

  • 1. Aberrant expression of the COX2/PGE
    Yoshitake R; Saeki K; Eto S; Shinada M; Nakano R; Sugiya H; Endo Y; Fujita N; Nishimura R; Nakagawa T
    Sci Rep; 2020 May; 10(1):7826. PubMed ID: 32385388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective detection of BRAF
    Aeschlimann L; Kehl A; Guscetti F; Posthaus C; Aupperle-Lellbach H; Rottenberg S; de Brot S
    Vet Comp Oncol; 2024 Jun; 22(2):295-302. PubMed ID: 38659202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a BRAF V595E-mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer.
    Kobayashi M; Onozawa M; Watanabe S; Nagashima T; Tamura K; Kubo Y; Ikeda A; Ochiai K; Michishita M; Bonkobara M; Kobayashi M; Hori T; Kawakami E
    Vet Comp Oncol; 2023 Jun; 21(2):221-230. PubMed ID: 36745053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF
    Maeda S; Yoshitake R; Chambers JK; Uchida K; Eto S; Ikeda N; Nakagawa T; Nishimura R; Goto-Koshino Y; Yonezawa T; Momoi Y
    Vet Pathol; 2021 Sep; 58(5):971-980. PubMed ID: 33205710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Author Correction: Aberrant expression of the COX2/PGE
    Yoshitake R; Saeki K; Eto S; Shinada M; Nakano R; Sugiya H; Endo Y; Fujita N; Nishimura R; Nakagawa T
    Sci Rep; 2020 Oct; 10(1):18820. PubMed ID: 33116270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coincidence of v-raf murine sarcoma viral oncogene homolog B mutation (V595E) with phosphorylated v-raf murine sarcoma viral oncogene homolog B in urothelial carcinoma in dogs.
    Yamasaki H; Uematsu Y; Hayashi Y; Yamashita M; Tei M; Uchida K; Ono K; Hirao H
    Can J Vet Res; 2022 Oct; 86(4):286-293. PubMed ID: 36211215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target.
    Jung H; Bae K; Lee JY; Kim JH; Han HJ; Yoon HY; Yoon KA
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs.
    Yamasaki H; Uematsu Y; Okano K; Ichikawa M; Tei M; Hirabayashi M; Uchida K; Ono K; Hirao H
    In Vitro Cell Dev Biol Anim; 2022 Dec; 58(10):898-911. PubMed ID: 36477686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
    Mochizuki H; Breen M
    Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
    Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M
    PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
    Heard JJ; Phung I; Potes MI; Tamanoi F
    BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma.
    Tagawa M; Tambo N; Maezawa M; Tomihari M; Watanabe KI; Inokuma H; Miyahara K
    PLoS One; 2020; 15(4):e0232365. PubMed ID: 32330187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic challenge in veterinary pathology: Detection of
    Chambers JK; Takahashi N; Kato S; Hashimoto Y; Goto-Koshino Y; Uchida K
    Vet Pathol; 2024 May; 61(3):335-338. PubMed ID: 38088189
    [No Abstract]   [Full Text] [Related]  

  • 14. Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling.
    Repasky GA; Zhou Y; Morita S; Der CJ
    Mol Carcinog; 2007 Dec; 46(12):958-70. PubMed ID: 17477350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
    Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C
    Genes Dev; 2012 Sep; 26(17):1945-58. PubMed ID: 22892241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
    Cronise KE; Hernandez BG; Gustafson DL; Duval DL
    Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma].
    Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF
    Ruiz-Saenz A; Atreya CE; Wang C; Pan B; Dreyer CA; Brunen D; Prahallad A; Muñoz DP; Ramms DJ; Burghi V; Spassov DS; Fewings E; Hwang YC; Cowdrey C; Moelders C; Schwarzer C; Wolf DM; Hann B; VandenBerg SR; Shokat K; Moasser MM; Bernards R; Gutkind JS; van 't Veer LJ; Coppé JP
    Nat Cancer; 2023 Feb; 4(2):240-256. PubMed ID: 36759733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.